Screener
Crinetics Pharmaceuticals CRNX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $12,879 | $22,611 |
| Accrued clinical trial costs | 10,084 | 7,369 |
| Accrued outside services and professional fees | 5,739 | 4,430 |
| Accrued research and development costs | 5,673 | 4,506 |
| Other accrued expenses | 3,112 | 2,854 |
| Total | $37,487 | $41,770 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's accounts payable?
- Crinetics Pharmaceuticals (CRNX) reported accounts payable of $12.88M in Q1 2026.
- How has Crinetics Pharmaceuticals's accounts payable changed year-over-year?
- Crinetics Pharmaceuticals's accounts payable decreased by 59.3% year-over-year, from $31.62M to $12.88M.
- What is the long-term trend for Crinetics Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's accounts payable has grown at a 32.3% compound annual growth rate (CAGR), from $5.59M to $22.61M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Crinetics Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude